Drug Trial Radar · NCT03525886
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia
Last checked: Nov 19, 2026Latest source record: May 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Apr 10, 2018
Primary completion
Apr 7, 2020
Study completion Apr 7, 2020
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- May 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, multiple-dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 in up to 30 adult female and male subjects (18 to 50 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). The study will include a sequential-cohort design with four NBI-74788 dosing regimens, with each regimen administered for 14 days.
Conditions
- CAH - Congenital Adrenal Hyperplasia
Interventions
NBI-74788Drug
Capsule, administered daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window AveragesTime frame: Baseline and Day 14
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Aurora, Colorado
Neurocrine Clinical Site
Indianapolis, Indiana
Neurocrine Clinical Site
Ann Arbor, Michigan
Neurocrine Clinical Site
Minneapolis, Minnesota
Neurocrine Clinical Site
Philadelphia, Pennsylvania
Neurocrine Clinical Site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.